Xstelos Holdings, Revenue Growth Rates (XTLS), Current and Historic Growth - CSIMarket
CSIMarket
 


Xstelos Holdings, Inc.  (XTLS)
 

XTLS's Revenue Growth by Quarter and Year

Xstelos Holdings,'s Revenue results by quarter and year




XTLS Revenue (in millions $) FY 2013 FY 2012 FY 2011 FY 2010
4th Quarter December -
3rd Quarter September 6.33
2nd Quarter June 6.55
1st Quarter March 5.63
FY 18.51





XTLS Revenue third quarter 2013 Y/Y Growth Comment
Xstelos Holdings, Inc. reported decrease in Revenue in the third quarter 2013 by -3.45% to $ 6.33 millions, from the same quarter in 2012.
Despite modest results in the third quarter 2013, contraction in Xstelos Holdings, Inc.'s Revenue appears to be smaller than Company's recent average decline.

Looking into third quarter 2013 results within Biotechnology & Pharmaceuticals industry 33 other companies have achieved higher Revenue growth. While Xstelos Holdings, Inc.' s Revenue decline of -3.45% ranks overall at the positon no. 2776 in the third quarter 2013.




XTLS Revenue ( Y/Y Growth %) 2013
2012 2011 2010
4th Quarter December - - - -
3rd Quarter September -3.45 % - - -
2nd Quarter June 12.93 % - - -
1st Quarter March -21.15 % - - -
FY   - - - -

Financial Statements
Xstelos Holdings,'s third quarter 2013 Revenue $ 6.33 millions XTLS's Income Statement
Xstelos Holdings,'s third quarter 2012 Revenue $ 6.56 millions Quarterly XTLS's Income Statement


XTLS Revenue (Quarter on Quarter Growth %)

2013
2012 2011 2010
4th Quarter December - 40.55 % - -
3rd Quarter September -3.3 % 13.1 % - -
2nd Quarter June 16.34 % -18.77 % - -
1st Quarter March -38.94 % - - -
FY (Year on Year)   - - - -




Revenue third quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #34
Healthcare Sector #312
Overall #2776

Revenue Y/Y Growth Statistics
High Average Low
12.94 % -3.88 % -21.12 %
(Jun 30 2013)   (Mar 31 2013)
Revenue third quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #34
Healthcare Sector #312
Overall #2776
Revenue Y/Y Growth Statistics
High Average Low
12.94 % -3.88 % -21.12 %
(Jun 30 2013)   (Mar 31 2013)

Revenue by Quarter for the Fiscal Years 2010, 2011, 2012, 2013

Xstelos Holdings,'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
40.54 % 1.49 % -38.91 %
(Dec 31 2012)  


XTLS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2013 Xstelos Holdings, Inc. disclosed fall in Revenue from the second quarter by -3.3% to $ 6.33 millions, from $ 6.55 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2013 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Xstelos Holdings,'s Revenue growth quarter on quarter, overall rank is 2470.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #271
Overall #2470
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #43
Healthcare Sector #271
Overall #2470
Revenue Q/Q Growth Statistics
High Average Low
40.54 % 1.49 % -38.91 %
(Dec 31 2012)  


XTLS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2013 Xstelos Holdings, Inc. disclosed fall in Revenue from the second quarter by -3.3% to $ 6.33 millions, from $ 6.55 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2013 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Revenue quarter on quarter growth. While Xstelos Holdings,'s Revenue growth quarter on quarter, overall rank is 2470.


Xstelos Holdings,'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2013)
12 Months Ending
(Jun 30 2013)
12 Months Ending
(Mar 31 2013)
12 Months Ending
(Dec 31 2012)
12 Months Ending
(Sep 30 2012)
Cumulative Revenue 12 Months Ending $ 27.74 $ 27.97 $ 27.22 $ 28.73 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) -0.81 % 2.76 % -5.25 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 661 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment


Xstelos Holdings, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 54
S&P 500 # 661
Cumulative Revenue growth Comment


Xstelos Holdings, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 54
S&P 500 # 661




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XTLS's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2013 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2013
Arrowhead Pharmaceuticals Inc 0.00%$ 0.000 millions
Iqvia Holdings Inc -0.31%$ -0.311 millions
Applied Genetic Technologies Corporation-0.39%$ -0.386 millions
Perspective Therapeutics Inc -0.60%$ -0.598 millions
American Bio Medica Corporation-1.14%$ -1.139 millions
Conmed Corporation-1.45%$ -1.446 millions
Fibrocell Science, Inc.-1.45%$ -1.449 millions
Cba Florida Inc -1.79%$ -1.787 millions
Bruker Corporation-1.97%$ -1.965 millions
Dynatronics Corporation-2.09%$ -2.090 millions
Micron Solutions Inc-2.31%$ -2.306 millions
Mylan N v -2.34%$ -2.340 millions
Msa Safety Inc-2.75%$ -2.749 millions
Lifevantage Corp-2.90%$ -2.896 millions
Retractable Technologies Inc-3.01%$ -3.006 millions
Antares Pharma Inc -3.13%$ -3.132 millions
Xstelos Holdings, Inc.-3.46%$ -3.460 millions
Quest Diagnostics Inc-3.48%$ -3.475 millions
Mural Oncology Plc-3.63%$ -3.630 millions
Harvard Bioscience Inc -3.70%$ -3.704 millions
Chemed Corporation-3.80%$ -3.800 millions
Merck and Co Inc -3.97%$ -3.969 millions
Oragenics Inc -4.12%$ -4.115 millions
First Choice Healthcare Solutions Inc -4.22%$ -4.224 millions
Utah Medical Products Inc-4.36%$ -4.357 millions
Beam Therapeutics Inc -4.59%$ -4.590 millions
China Health Industries Holdings Inc -4.65%$ -4.646 millions
Positron Corporation-5.14%$ -5.135 millions
Addus Homecare Corp-5.21%$ -5.211 millions
Allied Healthcare Products inc -6.23%$ -6.232 millions


About Xstelos Holdings, Revenue Growth Rates (XTLS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.